Business
FINAL RESULTS
FINAL RESULTS.
About this update from Immupharma Plc
[{"type":"text","content":"\n \nRNS Number : 0568A Immupharma PLC 24 May 2019 \n\n 24 MAY 2019\n \n \nImmuPharma PLC\n(\"ImmuPharma\" or the \"Company\")\n \nFINAL RESULTS ANNOUNCEMENT\nfor the twelve months ended 31 December 2018\n \nImmuPharma PLC (LSE:IMM), (\"ImmuPharma\" or the \"Company\"), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2018 (the \"Period\").\n \nKey Highlights (including post Period review)\n \n· Stable financial performance over the Period\no Cash balance of £4.9 million (31 December 2017: £2.7 million)\no Loss for the period of £7.2 million (31 December 2017: £6.2 million)\no Research and development expenses of £4.7 million (31 December 2017: £5.1 million)\no Basic and diluted loss per share of 5.19p (31 December 2017: 4.75p)\no A successful, £10 million (gross) fundraising completed in January 2018\no Acquired a 15% stake in Incanthera Limited for £2 million\nLupuzorTM \n \n· Top line results of the Company's pivotal Phase III trial of LupuzorTM were announced on 17 April 2018- key highlights include:\n· Lupuzor™ demonstrated a superior response rate over placebo (52.5% vs 44.6% \"responders\") in the primary analysis on the Full Analysis Set of all 202 patients. However, due to the high response rate in the placebo group, this superior response did not allow statistical significance to be reached (p = 0.2631) and the trial's primary end point was not met\n \n· Across the whole study population, in those patients who had anti-dsDNA autoantibodies, LupuzorTM demonstrated a superior response rate over placebo (61.5% vs 47.3%, p = 0.0967). Although these results were n...